Trials / Completed
CompletedNCT05376579
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
Impact of Mayzent (Siponimod) on Active Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study in Italy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 134 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational, multicenter, single-arm, prospective study conducted in Italy
Detailed description
Primary data will be collected over a period of three years. Medical history of participants will be collected including EDSS, MRI outcomes, relapses and previous medication to allow the estimation of the effects of siponimod treatment on an individual basis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | siponimod | Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care. |
Timeline
- Start date
- 2022-06-17
- Primary completion
- 2025-07-22
- Completion
- 2025-07-22
- First posted
- 2022-05-17
- Last updated
- 2025-12-18
Locations
24 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT05376579. Inclusion in this directory is not an endorsement.